Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-94.30m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CytomX Therapeutics Inc | 119.18m | 16.53m | 112.20m | 120.00 | 7.28 | -- | 6.04 | 0.9415 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Regulus Therapeutics Inc | 0.00 | -31.37m | 113.91m | 28.00 | -- | 1.06 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Karyopharm Therapeutics Inc | 140.46m | -146.34m | 115.32m | 325.00 | -- | -- | -- | 0.821 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Adicet Bio Inc | 0.00 | -139.79m | 118.33m | 143.00 | -- | 0.4572 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Annovis Bio Inc | 0.00 | -47.53m | 118.98m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Relmada Therapeutics Inc | 0.00 | -94.30m | 120.40m | 20.00 | -- | 1.67 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 120.53m | 20.00 | -- | 1.04 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
Vaxart Inc | 8.89m | -81.74m | 122.04m | 109.00 | -- | 2.19 | -- | 13.74 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
FibroGen Inc | 167.49m | -240.46m | 123.35m | 486.00 | -- | -- | -- | 0.7365 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Nuvectis Pharma Inc | 0.00 | -22.38m | 123.35m | 13.00 | -- | 8.80 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Tevogen Bio Holdings Inc | 0.00 | -67.33k | 124.57m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
Werewolf Therapeutics Inc | 16.22m | -41.58m | 127.76m | 46.00 | -- | 1.08 | -- | 7.88 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
aTyr Pharma Inc | 588.00k | -53.93m | 129.05m | 56.00 | -- | 1.51 | -- | 219.47 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Athira Pharma Inc | 0.00 | -116.19m | 129.17m | 65.00 | -- | 1.21 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 130.26m | 127.00 | -- | 1.64 | -- | 26.05 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.25m | 4.13% |
Deep Track Capital LPas of 31 Mar 2024 | 1.24m | 4.11% |
Vestal Point Capital LPas of 31 Mar 2024 | 1.20m | 3.98% |
Acadian Asset Management LLCas of 31 Mar 2024 | 1.18m | 3.92% |
Parsons Capital Management, Inc.as of 30 Jun 2024 | 975.95k | 3.23% |
Opaleye Management, Inc.as of 31 Mar 2024 | 759.00k | 2.52% |
Palo Alto Investors LPas of 31 Mar 2024 | 732.40k | 2.43% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 630.25k | 2.09% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 567.32k | 1.88% |
Millennium Management LLCas of 31 Mar 2024 | 341.45k | 1.13% |